• Leveljump Healthcare (JUMP) announced the company is acquiring a minority 13.1-per-cent stake Real Time Medical
  • Real Time is a private Ontario company founded by physicians with a vision to grow and operate a nationwide radiology collaboration service
  • The all-stock deal is worth approximately C$1.48 million
  • Real Time’s service network launched in 2008
  • LevelJump Healthcare is down 3.45 per cent, trading at $0.14 at 1:11 pm EST

Leveljump Healthcare (JUMP) announced the company is acquiring a minority 13.1-per-cent stake Real Time Medical.

Ontario-based Real Time is a private company founded and operated by physicians. Its vision is to grow and operate a nationwide radiology collaboration service for Canadian radiologists, with world-class, patented diagnostic workload balancing, workflow orchestration, peer learning and diagnostic operations software.

The all-stock deal is worth approximately C$1.48 million.

The equity interest in Real Time Medical was acquired through a mini-tender offer to that company’s shareholders on November 1, 2021.

“We are very excited about this investment and believe that with Real Time’s teleradiology operations and servicing in multiple provinces across Canada, that there is a natural complement to our core CTS operations. We are focused on expanding our telehealth solutions and offering critical care radiology support and this investment is another step in growing our company,” said Leveljump Chief Executive Officer Mitchell Geisler.

The closing of the deal remains subject to approval by the TSX Venture Exchange.

Toronto-based Leveljump is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology.

LevelJump Healthcare is down 3.45 per cent, trading at $0.14 at 1:11 pm EST.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.